Amgen (NQ:AMGN)

425.25 +12.41 (+3.01%)

Delayed Quote Updated: 10:51 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

73 74 Next >

Amgen's Options: A Look at What the Big Money is Thinking ↗

March 12, 2025

Via Benzinga

Is Eli Lilly Stock a Buy? ↗

March 11, 2025

Via The Motley Fool

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

3 Magnificent Growth Stocks to Buy in March ↗

March 08, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

March 07, 2025

Via The Motley Fool

2 Reasons to Watch AMGN and 1 to Stay Cautious

March 06, 2025

Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.

Via StockStory

Topics Stocks

Assessing Amgen: Insights From 9 Financial Analysts ↗

March 05, 2025

Via Benzinga

Behind the Scenes of Amgen's Latest Options Trends ↗

March 04, 2025

Via Benzinga

Looking Into Amgen's Recent Short Interest ↗

February 19, 2025

Via Benzinga

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 05, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform ↗

February 28, 2025

Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.

Via Benzinga

Topics ETFs Stocks

Amgen Unusual Options Activity For February 12 ↗

February 12, 2025

Via Benzinga

This Could Be the Best GLP-1 Stock to Buy in 2025 ↗

February 28, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys? ↗

February 25, 2025

Via The Motley Fool

Topics Stocks

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 11, 2025

Via Benzinga

Gilead Sciences (GILD) Q4 Earnings: What To Expect

February 10, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect.

Via StockStory

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

3 Fabulous Dividend Stocks to Buy in February ↗

February 09, 2025

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

February 09, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Via StockStory

We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗

February 07, 2025

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...

Via Stocktwits

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 06, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

February 05, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

February 05, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday? ↗

February 05, 2025

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.

Via Benzinga

Why Amgen (AMGN) Stock Is Trading Up Today

February 05, 2025

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter,...

Via StockStory

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.